Transforming growth factor-beta stimulates IL-1beta-induced monocyte chemoattractant protein-1 expression in human synovial cells via the ERK/AP-1 pathway. 2006

H Yoshimura, and K Nakahama, and O Safronova, and N Tanaka, and T Muneta, and I Morita
Department of Cellular Physiological Chemistry, Graduate School, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo-ku, Tokyo, 113-8549, Japan.

OBJECTIVE Transforming growth factor- beta (TGF-beta) has not only a fibrogenic role, but also monocyte/ macrophage chemotactic properties in a synovial joint. However, little is known about the effects of TGF-beta on monocyte chemoattractant protein-1 (MCP-1) expression in human synovial cells under inflammatory status. The aim of this study was to determine whether TGF-modulates MCP-1 production under the chronic inflammation, and to elucidate the cell signaling mechanism involved. METHODS Human synovial cells were exposed to IL-1beta, which mimics the environment of chronic inflammation. Production of MCP-1 protein and expression of MCP-1 mRNA were determined by ELISA and real-time PCR. RESULTS TGF-beta upregulated the expression of MCP-1 mRNA and protein with or without IL-1beta. TGF-beta and IL-1beta synergistically enhanced MCP-1 gene expression, and an AP-1 binding site was involved in the signal transduction. In addition, MEK inhibitor completely suppressed TGF-beta-induced MCP-1 production. CONCLUSIONS TGF-beta and IL-1beta synergistically enhance MCP-1 gene expression through the activation of the MEK/ERK1/2 pathways, which leads to AP-1 activation. The impairment of MCP-1 regulation by TGF-beta in resident synovial cells might represent an important mechanism of chronic inflammation and tissue fibrosis in a synovial joint. MCP-1 should be considered a valid target for therapeutic intervention.

UI MeSH Term Description Entries
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D015291 Transforming Growth Factors Hormonally active polypeptides that can induce the transformed phenotype when added to normal, non-transformed cells. They have been found in culture fluids from retrovirally transformed cells and in tumor-derived cells as well as in non-neoplastic sources. Their transforming activities are due to the simultaneous action of two otherwise unrelated factors, TRANSFORMING GROWTH FACTOR ALPHA and TRANSFORMING GROWTH FACTOR BETA. Transforming Growth Factor,Factor, Transforming Growth,Factors, Transforming Growth,Growth Factor, Transforming,Growth Factors, Transforming
D016212 Transforming Growth Factor beta A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins. Bone-Derived Transforming Growth Factor,Platelet Transforming Growth Factor,TGF-beta,Milk Growth Factor,TGFbeta,Bone Derived Transforming Growth Factor,Factor, Milk Growth,Growth Factor, Milk
D053583 Interleukin-1beta An interleukin-1 subtype that is synthesized as an inactive membrane-bound pro-protein. Proteolytic processing of the precursor form by CASPASE 1 results in release of the active form of interleukin-1beta from the membrane. IL-1 beta,Catabolin,Interleukin-1 beta,Interleukin 1 beta,Interleukin 1beta
D018808 Transcription Factor AP-1 A multiprotein complex composed of the products of c-jun and c-fos proto-oncogenes. These proteins must dimerize in order to bind to the AP-1 recognition site, also known as the TPA-responsive element (TRE). AP-1 controls both basal and inducible transcription of several genes. AP-1 Enhancer-Binding Protein,AP-1,AP-1 Enhancer Binding Protein,Activator Protein-1,AP 1 Enhancer Binding Protein,Activator Protein 1,Enhancer-Binding Protein, AP-1,Transcription Factor AP 1
D018932 Chemokine CCL2 A chemokine that is a chemoattractant for MONOCYTES and may also cause cellular activation of specific functions related to host defense. It is produced by LEUKOCYTES of both monocyte and lymphocyte lineage and by FIBROBLASTS during tissue injury. It has specificity for CCR2 RECEPTORS. Monocyte Chemoattractant Protein-1,Monocyte Chemotactic Protein-1,CCL2 Chemokine,Chemokine (C-C Motif) Ligand 2,Chemokines CCL2,Monocyte Chemotactic and Activating Factor,CCL2, Chemokine,CCL2, Chemokines,Chemoattractant Protein-1, Monocyte,Chemokine, CCL2,Chemotactic Protein-1, Monocyte,Monocyte Chemoattractant Protein 1,Monocyte Chemotactic Protein 1

Related Publications

H Yoshimura, and K Nakahama, and O Safronova, and N Tanaka, and T Muneta, and I Morita
July 1995, Journal of immunology (Baltimore, Md. : 1950),
H Yoshimura, and K Nakahama, and O Safronova, and N Tanaka, and T Muneta, and I Morita
November 1998, Journal of neuroimmunology,
H Yoshimura, and K Nakahama, and O Safronova, and N Tanaka, and T Muneta, and I Morita
June 1998, Arteriosclerosis, thrombosis, and vascular biology,
H Yoshimura, and K Nakahama, and O Safronova, and N Tanaka, and T Muneta, and I Morita
March 1995, Journal of neuroimmunology,
H Yoshimura, and K Nakahama, and O Safronova, and N Tanaka, and T Muneta, and I Morita
March 2003, Journal of immunology (Baltimore, Md. : 1950),
H Yoshimura, and K Nakahama, and O Safronova, and N Tanaka, and T Muneta, and I Morita
August 2001, Kidney international,
H Yoshimura, and K Nakahama, and O Safronova, and N Tanaka, and T Muneta, and I Morita
December 1991, Current opinion in dentistry,
H Yoshimura, and K Nakahama, and O Safronova, and N Tanaka, and T Muneta, and I Morita
January 2008, American journal of physiology. Renal physiology,
H Yoshimura, and K Nakahama, and O Safronova, and N Tanaka, and T Muneta, and I Morita
October 1991, Biochemical and biophysical research communications,
H Yoshimura, and K Nakahama, and O Safronova, and N Tanaka, and T Muneta, and I Morita
September 2001, European journal of pharmacology,
Copied contents to your clipboard!